Effient(TM) reduces the risk of cardiovascular death, heart attack and stroke in patients managed with common artery-opening procedure by 19 per cent compared with current standard of treatment(1)
Health Canada has taken an important step in helping to improve the health and quality of life of Canadians who suffer from heart attack and chest pain, with the approval of Effient(TM) (prasugrel hydrochloride). Effient is a new treatment that works quicker than the current standard of care for patients who suffer from Acute Coronary Syndromes (ACS) - an umbrella term for heart attack and unstable angina - who are being managed with a common artery-opening procedure called percutaneous coronary intervention (PCI). Effient will be available in Canada in the near future.
